Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Jul 2016

Morfini M, Dragani A, Paladino E, Radossi P, Di Minno G, Mazzucconi M G, Rossetti G, Barillari G, Napolitano M, Tagariello G

Abstract excerpt

INTRODUCTION: Pharmacokinetic (PK) studies on recombinant FIX concentrate, Nonacog alpha, were conducted with different sampling time designs which gave rise to not complete and homogenous outcomes. In addition, patient's FIX genotype/PK relationship has never been investigated. AIM: Investigate how different sampling times may affect PK parameters and try to find a FIX genotype/PK relationship. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Coagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Codon, Nonsense

Share to Drug Administration Schedule

Share to Factor IX

Share to Half-Life

Share to Hemophilia B

Share to ROC Curve

Source

Identifiers

PMID: 26988465
DOI: 10.1111/hae.12916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.PMID 26988465Read ↗

Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Semantic proximity Read ↗

Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.Semantic proximity Read ↗

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

Severe congenital protein C deficiency: description of a new mutation and prophylactic protein C therapy and in vivo pharmacokinetics.Semantic proximity Read ↗

Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.Semantic proximity Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

[Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].Semantic proximity Read ↗

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.Semantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

Transition considerations for extended half‐life factor productsSemantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.